Close
Nordic 9Nordic 9

Jeito Capital (investor - Private Equity)

France jeito.life
See something wrong or missing? Let us know
Offices:Paris

Jeito Capital is a private equity general partner firm headquartered in Paris, France and launched in 2020 by Rafaèle Tordjman

Average round investment:86.4M USD
Average number per year:3.7
Distribution: 2025 (3)2024 (3)2023 (5)2022 (6)2021 (2) See the entire list
Portfolio companies: Switzerland ReproNovoNetherlands AzafarosBelgium Augustine Therapeutics See the entire list
Mostly invests in: Switzerland Switzerland (6) Health services (22)
See the entire list

Showing 3 of 22 tracked investments in:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Jeito Capital mostly invests with:

You need an account to access this feature. Log in or create one from here.

Do you have a question? Talk to us.

Investors with similar profile to Jeito Capital

Name Criteria
Israel Canaan Partners
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom, France, Belgium, Germany, Denmark
  • Average number of deals per year: 3.9
  • Active last 12 months: Yes
United States Endeavor Catalyst
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Manufacturing, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Germany
  • Average number of deals per year: 4.0
  • Active last 12 months: Yes
United States Bain Capital
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing, Software Services
  • Similar business models: B2B
  • Common investees countries: Switzerland, United Kingdom, France, Netherlands, Germany, Denmark
  • Average number of deals per year: 4.2
  • Active last 12 months: Yes
Hong Kong Horizons Ventures
83%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Manufacturing, Software Services
  • Similar business models: B2B
  • Common investees countries: Switzerland, United Kingdom, Netherlands, Belgium, Germany
  • Average number of deals per year: 3.0
  • Active last 12 months: Yes
United States Invus
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing, Software Services
  • Similar business models: B2B
  • Common investees countries: Switzerland, United Kingdom, France, Belgium, Denmark
  • Average number of deals per year: 2.3
  • Active last 12 months: Yes
United States F-Prime Capital
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom, France, Netherlands
  • Average number of deals per year: 3.6
  • Active last 12 months: Yes
United Kingdom Advent Life Sciences
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing, Software Services
  • Similar business models: B2B
  • Common investees countries: Switzerland, United Kingdom
  • Average number of deals per year: 3.5
  • Active last 12 months: Yes
United Kingdom Cambridge Innovation Capital
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing, Software Services
  • Similar business models: B2B
  • Common investees countries: United Kingdom, Germany
  • Average number of deals per year: 3.3
  • Active last 12 months: Yes
United Kingdom One Peak Partners
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Manufacturing, Software Services
  • Similar business models: B2B
  • Common investees countries: Switzerland, United Kingdom, France, Germany, Denmark
  • Average number of deals per year: 3.3
  • Active last 12 months: Yes
United Kingdom Dawn Biopharma
82%
  • Range for average deal size: 50M - 100M USD
  • Similar verticals: Health services, Biotech, Pharma, Manufacturing
  • Similar business models: B2B
  • Common investees countries: Netherlands, Belgium, Denmark
  • Average number of deals per year: 3.0
  • Active last 12 months: Yes
Top